Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Discovery of the mechanisms behind epileptic seizures in autoimmune encephalitis

Published on: 07/04/2022 Reading time: 1 min
mécanismes
Retour à la recherche

An unprecedentedly precise exploration of the molecular and electrophysiological basis of a form of autoimmune encephalitis, conducted by the "Cellular Excitability and Neuronal Network Dynamics" team at the Paris Brain Institute, elucidates for the first time a scenario for the onset of epileptic seizures in this pathology. The results, published in Progress in Neurobiology, pave the way for the identification of new therapeutic targets for drug-resistant epilepsy.

Epileptic seizure and autoimmune encephalitis

Autoimmune encephalitis occurs as a result of an attack on the central nervous system by an individual's own immune cells. It is an important cause to look for in adult and childhood epilepsy, once the classic seizure triggers have been excluded: an autoimmune cause is thought to be involved in up to 30% of cases. The identification of an autoimmune cause also has major implications for medical treatment. In this case, anti-inflammatory drugs may be effective in treating the symptoms, while conventional anti-epileptic drugs are ineffective. Prompt treatment of autoimmune seizures is crucial because the neuronal hyperactivity associated with seizures can lead to significant cognitive and neurological consequences.

In autoimmune encephalitis, several proteins can be targeted by immune cells, such as NMDA receptors, leading to very severe neuropsychiatric disorders, or the synaptic protein LGI1, the most common target in patients with autoimmune epilepsy, which modulates the activity of the potassium channel KV1.1 at the synapse.

A new study model, combined with unprecedented cellular exploration

How can antibodies targeting the LGI1 protein induce such severe epileptic seizures? To explore this question, Paul Baudin, first author of the study, led by Vincent Navarro (Sorbonne University, AP-HP), associated with Séverine Mahon (Inserm) and Stéphane Charpier (Sorbonne University) in the team "Cellular Excitability and Dynamics of Neuronal Networks", blocked the KV1.1 channel in the motor cortex of rats. This resulted in seizures identical to those observed in patients. By analysing brain activity using electroencephalography (EEG), the researchers were able to identify a specific wave in the motor cortex preceding the onset of the seizure. These initial data reinforce the major homology between the patients and the animal model of encephalitis targeting the LGI1 protein, by blocking the KV1.1 channel.

Using this model, the researchers conducted an in-depth exploration at the cellular level of the consequences of blocking the KV1.1 channel. Combining multi-electrode recordings at the level of the motor cortex, set up with Delphine Roussel from the electrophysiology platform of the Paris Brain Institute, EPhys, and intracellular recordings, the expertise of Stéphane Charpier and Séverine Mahon in the team, they identified major changes in the activity of the synapses and the excitability of the neurons.

A scenario for the onset of seizures

Thanks to this unique approach, the researchers were able to propose a scenario for the onset of seizures and their very frequent repetition. After a first seizure, the neurons are inhibited and then gradually depolarise, i.e. the levels of activation and synchronisation of the neurons are increasingly high, until a new seizure is initiated. The study of the intrinsic characteristics of the neurons shows that they have become hyperexcitable, i.e. much more sensitive to the slightest stimulation. These data also explain the increase in the frequency of seizures in patients over time.

The Paris Brain Institute team suggests a central role for potassium channels in epilepsy associated with antibody-related autoimmune encephalitis. This result, for Prof. Vincent Navarro, opens up major perspectives for therapeutic research, notably on the anti-epileptic potential of potassium channel modulators.

Sources

https://pubmed.ncbi.nlm.nih.gov/35283238/
Baudin P, Whitmarsh S, Cousyn L, Roussel D, Lecas S, Lehongre K, Charpier S, Mahon S, Navarro V. Prog Neurobiol. 2022 Mar 10

Our news on the subject

Sclérose en plaques : identification d’une nouvelle molécule favorisant la remyélinisation
Multiple Sclerosis: Identification of a Molecule that Promotes Repair of the Nervous System
A molecule previously studied in the context of sleep disorders and attention deficit hyperactivity disorder (ADHD) is now, for the first time, revealing its potential in experimental models of multiple sclerosis (MS): it protects neurons and...
01.27.2026 Research, science & health
VignetteActu WBHF 2026
World Brain Health Forum 2026
More than one in three people will experience a brain disorder at some point in their lives. This reality, identified by the World Health Organization as a major public health priority, calls for unprecedented international mobilization. It is...
01.12.2026 Events
Une nouvelle approche pour évaluer les patients en état de conscience altérée
A New Approach to Assessing Patients with Disorders of Consciousness
In intensive care units, some patients who appear unconscious occupy a gray zone in their relationship to the world. To better diagnose them and predict their recovery potential, Dragana Manasova, Jacobo Sitt, and their colleagues have developed an...
01.08.2026 Research, science & health
Ne plus penser à rien : vers une signature cérébrale du blanc mental
Not Thinking About Anything: Toward a Brain Signature of Mind Blanking
What if the flow of our thoughts occasionally just stopped? Esteban Munoz-Musat, Lionel Naccache, Thomas Andrillon, and their colleagues at Paris Brain Institute and Monash University in Melbourne show that the sensation of “thinking about nothing”...
12.26.2025 Research, science & health
Deux nouvelles certifications pour les plateformes de l’Institut du Cerveau
Two new certifications for Paris Brain Institute’s core facilities
Paris Brain Institute’s core facilities were recently awarded two new certifications: ISO 9001 certification for ICM.Quant and ISO 20387 certification for its DNA & Cell Bank.
11.14.2025 Institutional
La dépression résistante possède une signature moléculaire spécifique
Treatment-resistant depression identified as a distinct molecular subtype
An international study published in Brain, Behavior, and Immunity shows that patients with treatment-resistant depression (TRD) have a unique biology, different from those who respond to standard therapies. More than 5,000 genes were found to behave...
11.03.2025 Research, science & health
See all our news